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Abstract  
 
The role of D1-like [D1, D5] and D2-like [D2, D3, D4] dopamine receptors and 
dopamine transduction via DARPP-32 in topographies of orofacial movement was 
assessed in restrained mice with congenic D4 vs D5 receptor vs DARPP-32 ‘knockout’. 
D4 and DARPP-32 mutants evidenced no material phenotype; also, there were no 
alterations in topographical responsivity to either the selective D2-like agonist RU 
24213 or the selective D1-like agonist SK&F 83959. In contrast, D5 mutants evidenced 
an increase in spontaneous vertical jaw movements, which habituated more slowly than 
in wildtypes, and a decrease in horizontal jaw movements; topographical responsivity to 
SK&F 83959 and RU 24213 was unaltered. D5 receptors regulate distinct topographies 
of vertical and horizontal jaw movement in an opposite manner. In assuming that the 
well-recognised role of the D1-like family in regulating orofacial movements involves 
primarily D1 receptors, a role for their D5 counterparts may have been overlooked.  
 
Key words: Orofacial movements; Dopamine receptors; D4 ‘knockout’; D5 ‘knockout’; 
DARPP-32 ‘knockout’; topographical assessment 
 
 4 
1. Introduction 
 
Regulation of orofacial movements constitutes a fundamental process given their 
criticality for consummatory behaviour, defensive and attack behaviours, self-care, 
vocalisation and, in higher mammals, verbal as well as non-verbal communication. 
While it is well recognized that the D1-like family of dopamine (DA) receptors exerts an 
important role in the regulation of orofacial movements (Rosengarten et al., 1983, 1986; 
Murray and Waddington, 1989; Collins et al., 1991; Waddington et al., 1995; Niznik et 
al., 2002), parcellating this role between individual family members [D1 (also known as 
D1A), D5 (also known as D1B)] has proved difficult. Specifically, in the absence of agents 
that can discriminate materially between D1 and D5 receptors, it has been assumed that 
the D1 receptor exerts a prepotent, if not exclusive, role on the basis of its high density 
localisation in brain regions such as the striatum, which are known to exert a 
fundamental role in the regulation of orofacial movements; conversely, the D5 receptor 
has a low density localisation in primarily cortical and limbic regions (Khan et al., 
2000; Di Chiara, 2002).  
The D2-like family plays a lesser role in the regulation of orofacial movements, both 
independently and especially via D1-like:D2-like interactions (Waddington et al., 1994, 
1995). Similarly, in the absence of agents that can discriminate materially between D2, 
D3 and D4 receptors, it has been assumed that the D2 receptor exerts a prepotent, if not 
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exclusive, role on the basis of its high density localisation in the striatum; conversely, 
D3 and particularly D4 receptors have a lower density striatal and primarily 
corticolimbic localisation (Tarazi and Baldessarini, 1999; Di Chiara, 2002).  
The phosphoprotein DARPP-32 [dopamine- and adenosine 
3′,5′-monophosphate-regulated phosphoprotein of 32 kilodaltons] is a critical 
component in the DA signaling cascade following activation both of D1-like and of 
D2-like receptors, particularly in relation to D1 and D2 receptors but possibly extending 
to other family members (Greengard et al., 1999; Greengard, 2001). However, any role 
in the regulation of orofacial movement topography is unknown.   
Recombinant DNA techniques have been applied by several groups to construct 
mice with targeted gene deletion [‘knockout’] of individual DA receptor subtypes 
(Sibley, 1999; Waddington et al., 2001). However, it is only recently that their potential 
to clarify the roles of individual DA receptor subtypes in regulating orofacial 
movements has been realised. Indeed, systematic assessment of such movements is only 
now being undertaken because of practical issues: mice are considerably smaller than 
rats and their orofacial movements more rapid, making for problems in assessment. 
These difficulties are exacerbated by considerable controversy, based primarily on data 
in rats, as to how orofacial movements should be defined phenomenologically and 
resolved empirically; generic terms such as ‘vacuous chewing’ enjoy widespread usage 
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despite uncertainty as to their relevance at a physiological level (Waddington, 1990; 
Waddington et al., 1998; Tomiyama et al., 2001, 2002).  
We have recently developed a novel system, combined with a physiologically based 
approach to categorisation and quantification, for the assessment of orofacial movement 
topography in mice (Tomiyama et al., 2001; Makihara et al., 2004). This has been 
applied to describe the phenotype of orofacial movements and topographical responses 
to D1-like and D2-like agonists in mice with congenic D1, D2 and D3 receptor ‘knockout’ 
(Tomiyama et al., 2002, 2004). We now describe the application of this technique to 
characterise topographically, in a complementary, comparative manner, the phenotype 
of orofacial movements, and responses to the D1-like agonist SK&F 83959 and the 
D2-like agonist RU 24213, in mice with congenic D4 vs D5 receptor vs DARPP-32 
‘knockout’. 
 
2. Experimental procedures 
 
2.1. Animals 
 
The original F2 hybrid strain [129/Ola × C57BL/6J] containing the mutated D4 
receptor allele was generated as reported previously (Rubinstein et al., 1997); animals 
from an essentially congenic line of D4 ‘knockouts’ [10 back-crosses into C57BL/6J] 
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were shipped to Dublin, where PCR analysis was used to identify congenic, 
homozygous mutants [D4-/-] and wildtypes [D4+/+] among the progeny of homozygous 
intermatings. The original F2 hybrid strain [129/SvJ1 × C57BL/6] containing the 
mutated D5 receptor allele was generated as reported previously (Hollon et al., 2002); 
animals from an essentially congenic line of D5 knockouts [7 back-crosses into 
C57BL/6] were shipped to Dublin, where PCR analysis was used to identify congenic, 
homozygous mutants [D5-/-] and wildtypes [D5+/+] among the progeny of heterozygous 
[D5+/-] intermatings (O’Sullivan et al., 2005). The original F2 hybrid strain [129/Ola × 
C57BL/6] containing the mutated DARPP-32 allele was generated as reported 
previously (Fienberg et al., 1998); animals from an essentially congenic line of 
DARPP-32 knockouts [10 back-crosses into C57BL/6] were shipped to Dublin, where 
PCR analysis was used to identify congenic, homozygous mutants [DARPP-32-/-] and 
wildtypes [DARPP-32+/+] among the progeny of homozygous intermatings (Nally et al., 
2003).  
 Following establishment of these breeding colonies in Dublin, experimental 
animals were shipped to Tokyo. There, they were maintained at 23 ± 1 oC and 55 ± 5% 
humidity on a 12 h /12 h (07.00 on; 19.00 off) light/dark schedule, with food and water 
available ad libitum. While approximately 75% of animals remained group-housed, 
approximately 25% of animals engaged in injurous fighting and were subsequently 
housed singly to conserve adequate experimental numbers; the necessity for such 
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housing occurred randomly and did not differ between the genotypes. Thereafter, they 
were maintained undisturbed for an adaptation period of at least two weeks before 
experiments were commenced. Young adult mice from litters of the same generational 
age were used in behavioural assessments, which took place between 08.30 and 11.30 to 
reduce any effects of circadian variation in orofacial movements. These studies were 
approved by the Research Ethics Committee of the Royal College of Surgeons in 
Ireland and the Animal Experimentation Committee of Nihon University School of 
Dentistry, and were conducted under license from the Department of Health and 
Children in accordance with European Communities Council Directive 86/609/EEC for 
the care and use of experimental animals. 
 
2.2. Restrictor system 
 
As described previously (Tomiyama et al., 2001), the system consisted of a 
‘restrictor’, by which mice were lightly restrained around the neck by a clear perspex 
collar attached to a horizontal platform; this allowed visual observation to be focused 
onto the orofacial region with minimal disturbance to movements other than locomotion, 
rearing and grooming. Circular collars were composed of two semicircular elements: 
one fixed to the platform and constituting a trough into which the neck was positioned; 
the other, inserted from above, completed light enclosure of the neck. Both the diameter 
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of the collar and its height above the platform were adjustable according to body size, to 
allow a comfortable posture to be maintained. A piece of absorbent paper was spread 
over the platform of the restrictor. To facilitate observation of the orofacial region, small 
mirrors were fixed in inclined positions under the snout of each mouse and lighting 
directed appropriately to illuminate the mouth. For each experimental session, five mice 
were placed individually into identical ‘restrictors’, each separated by cardboard 
dividers to minimize visual disruption and partially reduce auditory interference. The 
observer viewed each animal through slits in a cardboard screen in front of the array of 
‘restrictors’; these slits were positioned optimally in relation to the mouth, mirrors and 
illumination. 
 
2.3. Assessment of orofacial movement topography 
 
On the basis of the natural repertoire of behaviours of the mouse at an ethological 
level, together with dental physiology, orofacial movement topography was categorised 
into the following four elements: vertical jaw movements, horizontal [lateral] jaw 
movements, tongue protrusions, and chattering [high-frequency rhythmical jaw 
movements with incisor tapping] (Tomiyama et al., 2001); general head movements and 
vibrissae movements were also recorded.   
 A rapid time-sampling behavioural checklist technique, used previously to resolve 
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the topography of general exploratory and DA agonist-induced behaviour in knockout 
mice in an ethologically-based, unrestricted paradigm (Clifford et al., 2000, 2001; Ross 
et al., 2000; McNamara et al., 2002, 2003; O’Sullivan et al., 2005), was applied 
similarly to resolve the topography of orofacial movement (Tomiyama et al., 2001, 
2002): each of five mice was observed sequentially for 5 s periods at 25 s intervals; for 
each mouse, the presence or absence of each individual element (occurring alone or in 
any combination) was determined in each of the 5 s periods. For assessment of orofacial 
movement topography and its habituation profile without drug challenge, assessments 
commenced immediately after placement in restrictors, and continued for 30 min 
periods over a total duration of 210 min; mice were used on a single occasion only. For 
assessment of orofacial movement topography in drug challenge studies, mice were 
habituated to restrictors for a period of 3 h before administration of drug or vehicle, 
with assessments beginning thereafter over a total duration of 60 min; mice were used 
on two occasions only, separated by a drug-free interval of at least one week, with 
random allocation to one of the various treatments in each instance. All observations 
were made by an observer who was unaware of genotype and treatment for each animal. 
  
2.4. Drugs 
 
The selective D2-like agonist RU 24213 
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[N-n-propyl-N-phenyl-p-3-hydroxyphenylethylamine; Hoechst-Marion-Roussel, 
France] was dissolved in distilled water; the selective D1-like agonists SK&F 83959 
[3-methyl-6-chloro-7,8-dihydroxy-1-[3-methyl-phenyl]-2,3,4,5-tetrahydro-1H-3-benzaz
epine; RBI/SRI/NIMH Chemical Synthesis Program, USA] and A 68930 
[cis-(±)-1-(aminomethyl)-3,4-dihydro-3-phenyl-1H-2-benzopyran-5,6-diol 
hydrochloride; Tocris Cookson Ltd., UK] were dissolved in distilled water. Drugs or 
vehicle were injected subcutaneously into the flank in a volume of 2 ml/kg. 
 
2.5. Data analysis 
 
For determination of habituation profiles of orofacial movement topographies under 
restraint in the absence of drug treatment, total counts for each individual element were 
summed separately over the following periods: 0-30, 60-90, 120-150, 180-210 min; in 
drug challenge studies, these counts were summed over 0-60 min after administration. 
Data were expressed as means ± S.E.M. and analysed using repeated-measures 
analysis of variance (ANOVA) after square-root transformation in the absence of 
appropriate non-parametric techniques; univariate comparisons were made where 
overall effects on ANOVA were significant, using Student’s t-test or Mann-Whitney 
U-test after Kruskal-Wallis analysis as appropriate (McNamara et al., 2002, 2003; Ross 
et al., 2000; Tomiyama et al., 2001, 2002, 2004; Makihara et al., 2004; Nally et al., 2003, 
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2004; O’Sullivan et al., 2004, 2005). 
 
3. Results 
 
3.1. General parameters 
 
On examining 19 male congenic D4 mutants for orofacial topography under 
restraint, mean body weight [29 ± 1 g; mean age 178 ± 5 days] did not differ from 19 
wildtype controls [29 ± 1 g; mean age 174 ± 7 days]; No gross motor phenotype was 
apparent when animals were observed qualitatively for posture, reactivity to handling 
and general activity (see also Rubinstein et al., 1997). 
On examining 20 male congenic D5 mutants for orofacial topography under 
restraint, mean body weight [29 ± 1 g; mean age 180 ± 4 days] did not differ from 20 
male wildtype controls [29 ± 1 g; mean age 180 ± 2 days]. No gross motor phenotype 
was apparent when animals were observed similarly (see also Holmes et al., 2001; 
Hollon et al., 2002; O’Sullivan et al., 2005). 
On examining 20 male congenic DARPP-32 mutants for orofacial topography 
under restraint, mean age [152 ± 5 days; mean body weight 27 ± 1 g] was slightly older 
than that of 18 male wildtype controls [136 ± 2 days, P < 0.01; mean body weight 27 ± 
1 g]; the results of analyses reported below were unaltered on including age and weight 
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as covariates. No gross motor phenotype was apparent when animals were observed 
similarly (see also Fienberg et al., 1998; Nally et al., 2003, 2004). 
  
3.2. Topography of orofacial movements over habituation 
 
In wildtypes, vertical jaw movements, with movements of the head and vibrissae, 
were prominent initially but declined subsequently, while horizontal jaw movements 
increased in prominence over the habituation period; tongue protrusion and incisor 
chattering were present at modest levels throughout habituation (Fig. 1).  
In congenic D4 mutants, this topography of orofacial movements was essentially 
unaltered [no effects of genotype or genotype × time interactions] (data not shown). 
In congenic D5 mutants (Fig. 1), levels of vertical jaw movements were increased, 
and they habituated more slowly than in wildtypes [overall effect of genotype, F (1, 38) 
= 5.64, P < 0.05; genotype × time interaction, F (3, 114) = 4.54, P < 0.005]. Conversely, 
levels of horizontal jaw movements [overall effect of genotype, F (1, 38) = 12.54, P < 
0.005; no genotype × time interaction] and of vibrissae movements [overall effect of 
genotype, F (1, 38) = 5.16, P < 0.05; no genotype × time interaction] were decreased. 
Other topographies of orofacial movement were essentially unaltered. 
In congenic DARPP-32
 
mutants (Fig. 2), tongue protrusions were decreased 
[overall effect of genotype, F (1, 36) = 12.81, P < 0.01; no genotype × time interaction]. 
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Other topographies of orofacial movement were essentially unaltered.  
 
3.3. Topography of drug-induced orofacial movements 
 
In wildtypes, 0.016-0.4 mg/kg SK&F 83959 readily induced vertical but not 
horizontal jaw movements, with tongue protrusions and incisor chattering, together with 
movements of the head and vibrissae (Fig. 3); conversely, 0.1-1.0 mg/kg RU 24213 
reduced horizontal but not vertical jaw movements, with little effect on other 
topographies of orofacial movement (data not shown). These profiles of agonist 
responses were similar to those described previously in C57BL/6J mice (Tomiyama et 
al., 2001; Makihara et al., 2004).  
In congenic D4 mutants, the effects of SK&F 83959 to induce vertical jaw 
movements, tongue protrusions, incisor chattering and head movements were unaltered; 
there was slight variation in the induction of vibrissae movements between D4 mutants 
and wildtypes with increasing dose of SK&F 83959 [genotype × dose interaction, F (2, 
30) = 3.81, P < 0.05; no other genotype × dose interactions] (Fig. 3). The effect of RU 
24213 to reduce horizontal jaw movements was unaltered (data not shown).  
In congenic D5 mutants, these effects of SK&F 83959 and RU 24213 were 
essentially unaltered [no overall effects of genotype or genotype × dose interactions] 
(data not shown). 
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In congenic DARPP-32 mutants, these effects of SK&F 83959 and RU 24213 were 
essentially unaltered [no overall effects of genotype or genotype × dose interactions] 
(data not shown). In DARPP-32 mutants, studies with an additional D1-like agonist, A 
68930, were performed [see Discussion]; this agent induced vertical but not horizontal 
jaw movements, with tongue protrusions and incisor chattering, in a manner 
indistinguishable from SK&F 83959, as described previously (Tomiyama et al., 2001). 
These responses were unaltered in DARPP-32 mutants challenged with 0.068-0.2 
mg/kg A 68930; levels of horizontal jaw movements were increased in DARPP-32 
mutants in a manner unrelated to dose of A 68930 [overall effect of genotype, F (1, 32) 
= 7.97, P < 0.01; no genotype × dose interaction] (Fig. 4). 
 
4. Discussion 
 
Given the criticality of  orofacial movements for a variety of  fundamental 
mammalian behaviours [see 1. Introduction], these studies apply mutant mice to 
investigate the roles of  D4 and D5 members of, respectively, the D2-like and D1-like 
families of  DA receptor subtypes and the DA transduction mediator DARPP-32 in 
their regulation. A number of  methodological refinements have been incorporated 
into these studies: each ‘knockout’ is on a congenic as opposed to a mixed [hybrid] 
genetic background; a novel system is applied to allow the resolution and 
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quantification of  individual orofacial movement topographies; and comparisons are 
made with our recent reports on these same parameters, assessed using identical 
methods by the same investigators, in congenic D1, D2 and D3 mutants, as described 
previously in detail (Tomiyama et al., 2001, 2002, 2004). It should be emphasized 
that the present findings were conducted in male mutants. Therefore, the extent to 
which these findings generalize to females is unclear until systematic comparisons 
between the genders are conducted.  
Also, it was necessary to house approximately 25% of  animals singly [see 2. 
Experimental procedures]. Though isolation from weaning can effect dopamine 
receptor function (Gariepy et al., 1998), the present necessity for such housing 
occurred randomly at several months of age and did not differ between the genotypes; 
thus, though it may influence overall levels of orofacial movement, it is unlikely to 
account for phenotypic differences between genotypes. Furthermore, the present study 
involves resolution of orofacial movement under the stress of restraint. Though restraint 
is necessary to allow detailed topographical resolution in the mouse that is not possible 
under naturalistic conditions (Tomiyama et al., 2001), it cannot be excluded that some 
of the present effects are influenced by an interaction between genetic mutation and 
stress of restraint.     
Under these conditions, congenic D4 mutants evidenced no phenotypic effects in 
terms of orofacial movement topography under restraint. In relation to the D2-like 
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family, this would complement our findings in D2 and D3 mutants that it is the D2 
receptor that exerts some regulatory role to inhibit vertical jaw movements, with a 
limited role to facilitate tongue protrusions and incisor chattering, while D3 receptors 
exert only minor regulatory effects (Tomiyama et al., 2002, 2004). This profile may be 
in keeping with the known anatomical and physiological localisation of these receptors: 
D2 receptors have a dense localisation within the striatum, a region known to be critical 
for the regulation of orofacial movements; D3 receptors have a lower density 
localisation within circumscribed striatal regions and corticolimbic structures; D4 
receptors have a low density striatal and a particular corticolimbic localisation (Tarazi 
and Baldessarini, 1999; Di Chiara, 2002; Rivera et al., 2002a). However, as with all 
‘knockouts’, it cannot be excluded that aspects of phenotype are influenced also by 
compensatory mechanisms consequent to the developmental absence of the entity 
deleted (Clifford et al., 2000, 2001; Kelly et al., 1998; Sibley, 1999; Waddington et al., 
2001; McNamara et al., 2002, 2003; Tomiyama et al., 2002, 2004). 
In contrast, congenic D5 mutants under restraint evidenced an increase in vertical 
jaw movements, with delayed habituation, and a decrease in horizontal jaw movements 
and in movements of the vibrissae. In relation to the D1-like family, we have reported 
previously that D1 mutants evidence markedly reduced horizontal jaw movements, 
delayed habituation in vertical jaw movements, with reduction in tongue protrusions 
and incisor chattering (Tomiyama et al., 2002). This profile would be less in keeping 
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with the known anatomical and physiological localisation of these receptors: while D1 
receptors have a dense localisation within the striatum and in certain cortical regions, D5 
receptors have a low density striatal and a particular corticolimbic localisation (Khan et 
al., 2000; Di Chiara, 2002); yet D5 mutants exhibit phenotypic effects in terms of 
orofacial movement topography. Furthermore, the present differential regulatory effects 
of D5 vs D1 receptors would have been obscured by a composite index of jaw 
movements, such as widely-studied ‘vacuous chewing’, applied over what is commonly 
a limited time-frame: these differences are apparent only on resolving individual 
topographies of orofacial movement as they change over the prolonged process of 
habituation. 
Given the status of DARPP-32 as a critical mediator in the DA signaling cascade 
particularly through D1 and D2 receptors (Greengard et al., 1999; Greengard, 2001), the 
absence of any substantive orofacial movement phenotype in congenic DARPP-32 
mutants other than a decrease in tongue protrusions might be unexpected given the clear 
phenotypic effects in D1 and D2 mutants. However, these findings are consistent with 
our recent report (Nally et al., 2003) that DARPP-32 mutants show only a subtle 
phenotype in an ethologically based paradigm that resolves all components of behaviour 
in the mouse repertoire over the course of initial exploration of and subsequent 
habituation to the environment. Developmental absence of DARPP-32 in these mutants 
makes it possible that compensatory processes will be recruited to sustain functions 
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usually mediated by DARPP-32 under normal conditions (Waddington et al., 2001; 
Nally et al., 2003, 2004).  
       
 
Neither D4 nor D5 mutants evidenced material alterations in topographical 
responsivity to the D1-like agonist SK&F 83959 (Deveney et al., 1995; Niznik et al., 
2002), which evidences similar affinities for D1 and D5 receptors over their D2-like 
counterparts (O’Sullivan et al., 2004), or to the D2-like agonist RU 24213 (Clifford et al., 
2001; McNamara et al., 2002), which evidences similar affinities for D2, D3 and D4 
receptors over their D1-like counterparts (Roth, personal communication; O’Sullivan et 
al., in preparation). For D4 mutants this may reflect the limited involvement of D4 
receptors in such processes, even though a presence in the striatum is increasingly 
recognized (Rivera et al., 2002a), while for D5 mutants this may reflect in part a 
controversy as to the functional roles of putative D1-like receptors that are linked to a 
transduction mechanism other than/additional to adenylyl cyclase, and where the status 
of D5 receptors remains particularly unclear (Niznik et al., 2002); in D1 mutants, 
topographical orofacial movement responses to SK&F 83959 are attenuated (Tomiyama 
et al., 2002).  
Similarly, DARPP-32
 
mutants evidenced unaltered topographical responsivity to 
SK&F 83959 and RU 24213. The role of DARPP-32 in DA receptor signal transduction 
involves particularly D1-like receptors linked to adenylyl cyclase (Greengard et al., 
1999; Greengard, 2001), while SK&F 83959 is a D1-like agonist which has actions at 
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putative D1-like receptors linked to an alternative transduction system, perhaps 
phosphoinositide hydrolysis (Panchalingam and Undie, 2001; Jin et al., 2003). 
Therefore the isochroman A 68930, a full efficacy agonist at adenylyl cyclase-coupled 
D1-like receptors (DeNinno et al., 1990; Niznik et al., 2002), was also studied in 
DARPP-32 mutants. Topographical responses to A 68930 were unaltered, with an effect 
of genotype in the absence of any dose × genotype interaction indicating an overall 
increase in horizontal jaw movements in DARPP-32 mutants that was unrelated to 
treatment; this echoes a similar increase in general topographies of behaviour in 
DARPP-32 mutants that we have reported previously using an ethologically based 
paradigm, and which may reflect a subtle action of the stress of the injection procedure 
to reveal phenotypic effects not present under other conditions (Nally et al., 2003, 2004). 
Irrespective of these considerations, developmental absence of DARPP-32 is not 
associated with material alteration in topographical orofacial movement responses to 
D1-like and D2-like agonists; thus, the operation of compensatory processes may be 
relevant.  
In conclusion, the present data on orofacial movement topographies under restraint 
may suggest some involvement of cortical D5 mechanisms, as D5 receptors appear 
present in cortical regions that show some overlap with those regulating orofacial 
movement, at least in rats and non-human primates, and cortical regions can influence 
striatal DAergic function via well-described corticostriatal pathways (Zhang and 
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Sasamoto, 1990; Takada et al., 1998; Khan et al., 2000; Cools et al., 2002); our own 
work in rats indicates a role for cortical D1-like receptors in the regulation of orofacial 
movements, using pharmacological tools that cannot distinguish between D1 and D5 
receptors (Adachi et al., 2003). Alternatively, recent evidence suggests that the presence 
and physiological role of D5 receptors in the striatum and related basal ganglia regions 
may have been underestimated (Rivera et al., 2002b; Baufreton et al., 2003). Though the 
site(s) mediating these effects remain to be specified, the present data indicate an 
unexpected role for D5 receptors in the regulation of orofacial movements which 
complements our recent findings in relation to ethologically based assessments of 
behavioural repertoire (O’Sullivan et al., 2005). Similar to the more marked phenotype 
in D1 mutants (Tomiyama et al., 2002), the present findings in D5 mutants relate to 
specific orofacial movement topographies and how these change over habituation. This 
suggests a role for D5 as well as for D1 receptors in the processes by which behavioural 
change is ‘sculpted’ over time as an organism interacts with its environment.  
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Fig. 1. Phenotype of orofacial movement topographies under restaint in male wildtypes 
(filled squares) and congenic D5 mutants (open squares). Data are mean counts ± S.E.M. 
(n = 20 per group) for vertical and horizontal jaw movements, tongue protrusions, 
incisor chattering, and general head and vibrissae movements, over 30 min periods 
beginning at 0, 60, 120 and 180 min after commencing observations. Post-hoc tests: *P 
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< 0.05, *** P < 0.001 vs wildtypes.
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Fig. 2. Phenotype of orofacial movement topographies under restaint in male wildtypes 
(filled squares) and congenic DARPP-32
 
mutants (open squares). Data are mean counts 
± S.E.M. (n = 18-20 per group) for vertical and horizontal jaw movements, tongue 
protrusions, incisor chattering, and general head and vibrissae movements, over 30 min 
periods beginning at 0, 60, 120 and 180 min after commencing observations. Post-hoc 
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test: *P < 0.05 vs wildtypes.
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Fig. 3. Phenotype of orofacial movement topographies under restraint in wildtypes 
(filled columns) and congenic D4 mutants (open columns) following challenge with 
0.016- 0.4 mg/kg SK&F 83959 or vehicle (V). Data are mean counts ± S.E.M. (n = 5-7 
per group) for vertical and horizontal jaw movements, tongue protrusions, incisor 
chattering, and general head and vibrissae movements, over a 60 min period. Post-hoc 
tests: bP < 0.01, cP < 0.001 vs vehicle. 
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Fig. 4. Phenotype of orofacial movement topographies under restraint in wildtypes 
(filled columns) and congenic DARPP-32
 
mutants (open columns) following challenge 
with 0.068- 0.2 mg/kg A 68930 or vehicle (V). Data are mean counts ± S.E.M. (n = 6-7 
per group) for vertical and horizontal jaw movements, tongue protrusions, incisor 
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chattering, and general head and vibrissae movements, over a 60 min period. Post-hoc 
tests: aP < 0.05, bP < 0.01, cP < 0.001 vs vehicle; * P < 0.05 vs wildtypes. 
 
